BVE Insights Series Debrief - La Jolla, CA

LIFE SCIENCES VENTURE CAPITAL

BVE INSIGHTS SERIES SEPTEMBER 26, 2022 LA JOLLA, CA PRIVATE EVENT

RESEARCH & STRATEGIES FOR THE FUTURE OF HEALTHCARE

BVE INSIGHTS SERIES LIFE SCIENCES VENTURE CAPITAL Powerful trends are reshaping the healthcare industry. Government agencies, institutions of higher education, and life sciences entrepreneurs are working collectively to unlock the patient care potential of cannabis and psilocybin as treatments for debilitating physical and mental health conditions, and Pharma has taken notice. Current key investment drivers include: Regulatory agencies receptive to change, research funding and access; An increase in entrepreneurship coupled with a lack of institutional capital; Innovation solving for large, unmet medical needs, and; An imminent wave of M&A transactions.

Bonaventure Equity's differentiated venture strategy and purpose-built platform solves for the complexities of investing in the space. Targeting Seed and Series A stage companies, BVE is positioned to negotiate preferential terms, provide operational resources, and harvest optimal returns.

GOVERNMENT AGENCY RECEPTIVITY Once off limits, government agencies are receptive to cannabis and psychedelics as viable options for treating significant unmet medical needs.

U.S. Food & Drug Administration (FDA)

U.S. Drug Enforcement Administration (DEA)

National Institutes of Health (NIH)

Defense Advanced Research Projects Agency (DARPA)

U.S. Department of Agriculture (USDA)

Approved Epidiolex in 2018, the first plant derived CBD drug approved by the agency. Sold in 2021 for $7.2 billion.

Began expediting controlled substances research licenses in 2018 and has proposed a massive increase in research grade production of cannabis and psilocybin of 6300% in 2022.

Issued first federal research funding in 50 years to Johns Hopkins University in 2021. Members of the Senate issued a letter to NIH requesting expanded research of psychedelics.

In 2022, provided $26.9 million in funding to the University of North Carolina’s Medical School to fund psychedelic research as a part of the Focused Pharma mental health program.

The 2018 Farm Bill differentiated hemp from cannabis, legalized regulated hemp production and directed the USDA to develop the regulatory framework for hemp farming in the US.

BV B V EE. .VVCC

PRESENTATION DEBRIEF ADDRESSABLE MARKET FOR CURRENT RESEARCH Government agencies, academic and research institutions are investing in cannabis and psychedelics as viable options for treating significant unmet medical needs, and with the right partner, pioneering life sciences companies are positioned to deliver patient care and service a $2.7 trillion dollar market.

THREE SIMPLE TAKEAWAYS

1

PSYCHEDELIC DRUGS ARE EFFICACIOUS.

2

THEY ARE SAFE AND WELL TOLERATED.

3

THEY ARE ON THE CUSP OF COMPLETELY DISRUPTING HEALTHCARE.

THERAPEUTIC INDICATION

US POPULATION

US HEALTHCARE COSTS

Parkinson's Disease

1.1 million

$52 billion

Fibromyalgia

6-12 million

$18 billion

Treatment Resistant Depression 4.4 million

$326 billion

Post-traumatic Stress Disorder

15 million

$232 billion

Pain

50 million

$635 billion

Alzheimer's Disease

16 million

$244 billion

Mental Health

52.9 million

$225 billion

Sexual Wellness

F: 43% • M: 31% $11 billion

Eating Disorders

28 million

Cancer Treatment

1.7 million/Year $240 billion

Traumatic Brain Injury

5.3 million

$48.3 billion

Sleep Aids

9 million

$118 billion

Alcohol Use Disorder

14.5 million

$249 billion

Opioid Use Disorder

10 million

$35 billion

Nicotine Use Disorder

35 million

$170 billion

Epilepsy

3-4 million

$8.6 billion

$64.7 billion

$2.7 Trillion

CONTACT ROSS O'BRIEN

GREG MCKEE

Founder & Managing Partner

Managing Partner

(646) 554-5058

(858) 729-3011

ross@bve.vc

greg@bve.vc

The BVE Insights Series continues in Manhattan Beach on Friday, November 4, 2022. To secure your space at this private event, please email Brock Byers at brock@bve.vc.

BBVV E . V VCC

VENTURE FURTHER